Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03114111 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis
A Early Phase 1 study of Seborrheic Dermatitis, sponsored by University of California, Davis.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03114111 is a Early Phase 1 study of Seborrheic Dermatitis that has completed, run by University of California, Davis. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03114111, a Early Phase 1 study of Seborrheic Dermatitis, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is: 1. To determine the efficacy of photodynamic therapy (PDT) in the treatment of seborrheic dermatitis. 2. To determine how PDT alters the skin microbiome in subjects with seborrheic dermatitis before and after treatment. 3. To determine how PDT alters sebum secretion rates in subjects with seborrheic dermatitis before and after treatment. The researchers hypothesize that PDT will be efficacious in the treatment of seborrheic dermatitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG aminolevulinic acid (ALA)
Study Locations (1)
California
- University of California, Davis - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-01 |
| Est. Completion | 2019-12-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03114111
The ClinicalTrials.gov registry entry for NCT03114111 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seborrheic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03114111 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03114111 about?
NCT03114111 is a clinical study titled "Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis". The purpose of this study is: 1. To determine the efficacy of photodynamic therapy (PDT) in the treatment of seborrheic dermatitis. 2. To determine how PDT alters the skin microbiome in subjects with seborrheic dermatitis before and after treatment. 3. To determine how PDT alters sebum secretion ra...
What is the current status of trial NCT03114111?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2017-01. Estimated completion is 2019-12-04.
What conditions does trial NCT03114111 study?
This clinical trial studies the following conditions: Seborrheic Dermatitis.
What interventions are being tested in trial NCT03114111?
The interventions under investigation include: Placebo (DRUG), aminolevulinic acid (ALA) (DRUG).
Who is sponsoring clinical trial NCT03114111?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03114111 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seborrheic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.